Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 13/20 | 0.50 |
| ▸ | MMP3 | P08254 | 9/20 | 0.50 |
| ▸ | MMP1 | P03956 | 7/20 | 0.50 |
| ▸ | MMP12 | P39900 | 3/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7761489 | 0.75 | SYNJ2 (0.39) | MMP2MMP3MMP1MMP12MMP9 | |
| SCHEMBL7762255 | 0.74 | MMP2 (0.49) | MMP2MMP3MMP12MMP9MMP13 | |
| SCHEMBL7758600 | 0.74 | MMP12 (0.60) | MMP2MMP3MMP12MMP9MMP13 | |
| SCHEMBL7758650 | 0.74 | MMP2 (0.53) | MMP2MMP3MMP1MMP12MMP9 | |
| SCHEMBL7762343 | 0.73 | MMP2 (0.52) | MMP2MMP3MMP1MMP12MMP9 | |
| SCHEMBL7763219 | 0.73 | MMP2 (0.52) | MMP2MMP3MMP1MMP12MMP9 | |
| SCHEMBL7763214 | 0.73 | MMP2 (0.52) | MMP2MMP3MMP1MMP12MMP9 | |
| SCHEMBL7758480 | 0.73 | MMP2 (0.47) | MMP2MMP3MMP12MMP9MMP13 | |
| SCHEMBL7765346 | 0.73 | MMP2 (0.47) | MMP2MMP3MMP12MMP9MMP13 | |
| SCHEMBL7758483 | 0.73 | MMP2 (0.47) | MMP2MMP3MMP12MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |